Equities research analysts predict that United Therapeutics Corporation (NASDAQ:UTHR) will report $430.87 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for United Therapeutics Corporation’s earnings, with the highest sales estimate coming in at $442.51 million and the lowest estimate coming in at $415.90 million. United Therapeutics Corporation posted sales of $408.20 million in the same quarter last year, which would indicate a positive year over year growth rate of 5.6%. The company is scheduled to announce its next earnings results before the market opens on Wednesday, October 25th.

On average, analysts expect that United Therapeutics Corporation will report full-year sales of $430.87 million for the current fiscal year, with estimates ranging from $1.59 billion to $1.72 billion. For the next fiscal year, analysts anticipate that the business will post sales of $1.38 billion per share, with estimates ranging from $1.22 billion to $1.55 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow United Therapeutics Corporation.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). The business had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $4.42 earnings per share.

UTHR has been the subject of several research reports. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 3rd. Jefferies Group LLC reissued a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a report on Friday, July 14th. TheStreet cut United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. ValuEngine cut United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Finally, UBS AG reissued a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $132.09.

Shares of United Therapeutics Corporation (UTHR) traded up 1.64% on Tuesday, reaching $121.01. The company’s stock had a trading volume of 399,733 shares. The company’s 50 day moving average is $122.15 and its 200-day moving average is $125.75. The firm has a market cap of $5.26 billion, a price-to-earnings ratio of 14.03 and a beta of 1.49. United Therapeutics Corporation has a 1-year low of $110.90 and a 1-year high of $169.89.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,248 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $126.41, for a total transaction of $157,759.68. Following the transaction, the chief executive officer now owns 2,317 shares in the company, valued at approximately $292,891.97. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 2,176 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $127.11, for a total value of $276,591.36. Following the transaction, the chief executive officer now owns 3,245 shares in the company, valued at approximately $412,471.95. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,087 shares of company stock valued at $2,149,984. 7.80% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. HPM Partners LLC increased its stake in United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after acquiring an additional 15 shares during the period. First Allied Advisory Services Inc. increased its stake in United Therapeutics Corporation by 0.4% during the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after acquiring an additional 19 shares during the period. Nomura Asset Management Co. Ltd. increased its stake in United Therapeutics Corporation by 0.3% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock worth $1,712,000 after acquiring an additional 40 shares during the period. Fisher Asset Management LLC increased its stake in United Therapeutics Corporation by 1.4% during the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 45 shares during the period. Finally, Synovus Financial Corp increased its stake in United Therapeutics Corporation by 1.2% during the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after acquiring an additional 69 shares during the period.

TRADEMARK VIOLATION NOTICE: “$430.87 Million in Sales Expected for United Therapeutics Corporation (UTHR) This Quarter” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/20/430-87-million-in-sales-expected-for-united-therapeutics-corporation-uthr-this-quarter.html.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics Corporation (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.